Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Susmed Drops Reimbursement Request for Insomnia App
Tokyo-based med tech Susmed said on January 29 that it is withdrawing its request for the health coverage of its cognitive behavioral therapy app for insomnia, Med CBT-i, under the FY2024 reimbursement fee revision. The move comes after a healthcare…
To read the full story
Related Article
- Susmed Wins Partial Change Approval for Insomnia App, Seeks Coverage
September 8, 2025
- MHLW Panel to Further Review Positioning of Susmed’s Insomnia App
July 31, 2025
- Susmed Seeks Partial Change of Approval for Insomnia App towards Coverage
September 3, 2024
- Susmed Bags Japan Approval for Insomnia App
February 20, 2023
- Susmed’s Insomnia App in Line for Approval as Early as January
December 20, 2022
- Susmed’s Insomnia App Up for PAFSC Review on December 19
December 6, 2022
- Shionogi Gets Commercial Rights to Susmed’s Insomnia App
December 28, 2021
BUSINESS
- Leqembi Global Sales Hit 61.8 Billion Yen in April-December: Eisai
February 9, 2026
- Marubeni Rolls Out Antibiotic Xenleta in China
February 9, 2026
- HLC, Mochida Set to Launch Japan PIII Trial of Umbilical Cord-Derived MSC
February 9, 2026
- Japan Ethical Drug Sales Up 3.2% in December: Crecon
February 9, 2026
- Lilly Discloses Japan Filing for Orforglipron, Starting with Obesity
February 6, 2026
Japan’s Biological Raw Material Rules Enter Major Revision; Clarity on Benefits and Safety Holds Key
Japan is poised to make the most sweeping revision in eight years to the Standards for Biological Raw Materials —…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…